Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.68 |
| ▸ | NPC1 | O15118 | 6/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10238306 | 0.83 | MAPT (0.65) | RAB9ANPC1ALDH1A1GAAADORA3 | |
| SCHEMBL9901433 | 0.81 | P4HTM (0.58) | RAB9ANPC1CA12CA9L3MBTL1 | |
| SCHEMBL13881198 | 0.81 | RAB9A (1.00) | RAB9ANPC1CA12CA9L3MBTL1 | |
| SCHEMBL29960964 | 0.80 | NPC1 (0.74) | RAB9ANPC1L3MBTL1ALDH1A1GLA | |
| SCHEMBL3794850 | 0.80 | NPC1 (0.74) | RAB9ANPC1L3MBTL1ALDH1A1GLA | |
| SCHEMBL5254742 | 0.79 | F10 (0.77) | RAB9ANPC1ALDH1A1GAAMEN1 | |
| SCHEMBL16583878 | 0.79 | NPC1 (0.73) | RAB9ANPC1L3MBTL1ALDH1A1GLA | |
| SCHEMBL28577755 | 0.79 | NPC1 (0.73) | RAB9ANPC1L3MBTL1ALDH1A1GLA | |
| SCHEMBL6353000 | 0.79 | MAPT (0.64) | ALDH1A1GAAADORA3ADORA2AADORA2B | |
| SCHEMBL26074396 | 0.78 | RAB9A (1.00) | RAB9ANPC1L3MBTL1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403812-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2016-08-02 | — | — | US | disclosed |
| US-9403812-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2016-08-02 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO University Hospital, HF (NO) | 2014-01-30 | — | — | US | disclosed |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO University Hospital, HF (NO) | 2014-01-30 | — | — | US | disclosed |
| CN-103429583-A | Triazole derivatives as WNT signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF | 2013-12-04 | — | — | CN | disclosed |
| EP-2649063-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | Oslo University Hospital HF (NO) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012076898-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076898-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | RAB9A 2940/4885NPC1 1200/4885CA12 4221/4885 |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | RAB9A 2977/4885NPC1 1224/4885CA12 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.